Hormone-Related and Drug-Induced Osteoporosis: A Cellular and Molecular Overview
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Osteoporosis resulting from an imbalance of bone turnover between resorption and formation is a critical health issue worldwide. Estrogen deficiency following a nature aging process is the leading cause of hormone-related osteoporosis for postmenopausal women, while glucocorticoid-induced osteoporosis remains the most common in drug-induced osteoporosis. Other medications and medical conditions related to secondary osteoporosis include proton pump inhibitors, hypogonadism, selective serotonin receptor inhibitors, chemotherapies, and medroxyprogesterone acetate. This review is a summary of the cellular and molecular mechanisms of bone turnover, the pathophysiology of osteoporosis, and their treatment. Nuclear factor-κβ ligand (RANKL) appears to be the critical uncoupling factor that enhances osteoclastogenesis. In contrast, osteoprotegerin (OPG) is a RANKL antagonist secreted by osteoblast lineage cells. Estrogen promotes apoptosis of osteoclasts and inhibits osteoclastogenesis by stimulating the production of OPG and reducing osteoclast differentiation after suppression of IL-1 and TNF, and subsequent M-CSF, RANKL, and IL-6 release. It can also activate the Wnt signaling pathway to increase osteogenesis, and upregulate BMP signaling to promote mesenchymal stem cell differentiation from pre-osteoblasts to osteoblasts rather than adipocytes. Estrogen deficiency leads to the uncoupling of bone resorption and formation; therefore, resulting in greater bone loss. Excessive glucocorticoids increase PPAR-2 production, upregulate the expression of Dickkopf-1 (DKK1) in osteoblasts, and inhibit the Wnt signaling pathway, thus decreasing osteoblast differentiation. They promote osteoclast survival by enhancing RANKL expression and inhibiting OPG expression. Appropriate estrogen supplement and avoiding excessive glucocorticoid use are deemed the primary treatment for hormone-related and glucocorticoid-induced osteoporosis. Additionally, current pharmacological treatment includes bisphosphonates, teriparatide (PTH), and RANKL inhibitors (such as denosumab). However, many detailed cellular and molecular mechanisms underlying osteoporosis seem complicated and unexplored and warrant further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calcium intake in bone health: a focus on calcium-rich mineral waters
Vannucci, L., Fossi, C., Quattrini, S., Guasti, L., Pampaloni, B., Gronchi, G., Giusti, F., Romagnoli, C., Cianferotti, L., Marcucci, G., et al. (2018) · Nutrients · doi:10.3390/nu10121930 · Cited by 245
Glüer, C.-C., Marin, F., Ringe, J. D., Hawkins, F., Möricke, R., Papaioannu, N., Farahmand, P., Minisola, S., Martínez, G., Nolla, J. M., et al. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1870 · Cited by 171
Mechanisms of glucocorticoid-induced osteoporosis.
Canalis, E. (2003) · Current Opinion in Rheumatology · doi:10.1097/00002281-200307000-00013 · Cited by 164
Ishida, Y., & Heersche, J. N. M. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.12.1822 · Cited by 155
Sciannamblo, M., Russo, G., Cuccato, D., Chiumello, G., & Mora, S. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2823 · Cited by 82 · cited 1×
“reported a decreased bone density in young patients with congenital adrenal hyperplasia receiving glucocorticoids compared to healthy controls [66].”
BackgroundUncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis
Hansen, K. E., Wilson, H. A., Zapalowski, C., Fink, H. A., Minisola, S., & Adler, R. A. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.362 · Cited by 65
Gonadotropin-releasing hormone agonist and add-back therapy: what do the data show?
Surrey, E. S. (2010) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e32833b35a7 · Cited by 64
Bone mineral density in adolescent and young adult women on injectable or oral contraception
Cromer, B. A. (2003) · Current Opinion in Obstetrics and Gynecology · doi:10.1097/00001703-200310000-00002 · Cited by 61 · cited 1×
“Cromer reported that young women might fail to achieve optimal peak bone mass due to use of DMPA as a contraceptive [97].”
BackgroundÖzdemir, S., Çelik, Ç., Görkemli, H., Kıyıcı, A., & Kaya, B. (2009) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2009.03.016 · Cited by 54 · cited 2×
“When it comes to the factors affecting menopause, surgical menopause is associated with a higher osteoporosis rate than natural menopause [18].”
Background
Cited by
Bone-derived factors mediate crosstalk between skeletal and extra-skeletal organs
He, T., Qin, L., Chen, S., Huo, S., Li, J., Zhang, F., Yi, W., Mei, Y., & Xiao, G. (2025) · Bone Research · doi:10.1038/s41413-025-00424-1 · Cited by 58
“50 In addition, OPN is overexpressed in skeletal muscle injuries that occur due to sports or trauma.”
Metadata
- Authors
- Wang, L.-T., Chen, L.-R., & Chen, K.-H.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-03-18
- Volume
- 24
- Issue
- 6
- Pages
- 5814
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4327966078
- Cited by
- 166
- References
- 9
- FWCI
- 12.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hormone-Related and Drug-Induced Osteoporosis: A Cellular and Molecular Overview. https://app.cochat.ai/papers/10.3390/ijms24065814
- The paper
- Wang, L.-T., Chen, L.-R., & Chen, K.-H. (2023). Hormone-Related and Drug-Induced Osteoporosis: A Cellular and Molecular Overview. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24065814
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.